Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients…
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company…
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –SAN…
- Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025…
Second Quarter Net Sales Increased 2.4% to $16.7 Million, Compared to $16.3 Million for the Second Quarter of 2024Net sales…
- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA BOSTON, MASSACHUSETTS, Aug.…
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in…
Peer-reviewed publications continue to validate Excimer Laser efficacy in vitiligo and treatment STRATA updates status of non-Excimer laser false advertising litigation…
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring…
Cutting-edge solution enables a consistent user authentication experience across devices, applications, and workflows to drive productivity while bolstering security and…